Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States.

{"article_title":"Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States.","author":"Nechi, Regina Nwamaka , Rane, Amey , Karaye, Rukayyah M , Ndikumukiza, Cyrille , Alsahali, Saud , Jatau, Abubakar I , Zoni, Cesar Rodrigo , Alanzi, Abdullah , Karaye, Ibraheem M , Yunusa, Ismaeel","journal_title":"Clinical therapeutics","issn":"1879-114X ; Electronic","isbn":"","publication_date":"20230701","volume":"45","issue":"7","first_page":"627","page_count":"6","accession_number":"37270374","doi":"10.1016\/j.clinthera.2023.05.002","publisher":"Excerpta Medica","doctype":"Journal Article; Research Support","subjects":"Pharmacology ","interest_area":["Cardiology"," Emergency Medicine"],"abstract":"Declaration of Competing Interest None.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=37270374&authtype=shib&custid=ns346513"}